^
Association details:
| Biomarker: | FGFR1 amplification |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | volasertib (NBL-001) (PLK1 inhibitor) + BI2536 (PLK1 inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P71.03 - A New Combination Therapy for FGFR1-Amplified Lung Cancer
Published date:
08/18/2021
Excerpt:
Pharmacological combination of FGFR1 with PLK1 inhibitor (BI2536/BI6727) shows synergistic anti-proliferative effects in FGFR1-amplified lung cancer cells. Combination treatment (FGFRi/PLK1i) potently suppresses FGFR1-amplified lung cancer growth in mouse xenograft models.
